We advised Oxipit, an AI medical imaging application developer, on a major partnership deal. On 17 February 2025, Unilabs, a leading European diagnostic services provider, announced the selection of Oxipit’s AI solutions to be deployed for chest X-rays throughout Unilabs’ European network.
With this collaboration, two great companies are paving the way to better and more efficient healthcare.
Oxipit is the future of medical imaging
Founded in 2017, Oxipit received CE certification for its AI solution, ChestEye, in 2019. In April 2022, Oxipit launched ChestLink – the world’s first autonomous AI imaging application that is CE Class and IIb certified, and capable of identifying normal chest X-ray studies with 99.9% sensitivity.
Revolutionising radiology workflows
As the press release states, this partnership will integrate Oxipit’s AI solutions, ChestLink and ChestEye, into Unilabs’ radiology workflows. Collaboration with Oxipit will make radiology workflows more efficient by automating the review of normal chest X-rays, triage and second-reading capabilities. This allows radiologists to concentrate on urgent and complex cases, leading to faster, more accurate reports and better patient care. (See the full press release here.)
Oxipit and Unilabs’ partnership will have an international impact. The agreement covers the option to use Oxipit’s solutions throughout the entire Unilabs group in Europe, with the initial rollout starting in Portugal.
Our services and client team
Our team took the lead in drafting the framework agreement for using these software solutions across Europe, and represented Oxipit throughout the negotiations with Unilabs. The advisory included aspects related to general contract law as well as our specific expertise in medical devices law, AI-related legal issues, and data protection law.
The client team was led by partner Lise-Lotte Lääne, and supported by partner Mihkel Miidla and associate Jürgen Adamson.
